U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Primary hyperoxaluria, type II(HP2)

MedGen UID:
120616
Concept ID:
C0268165
Disease or Syndrome
Synonyms: D-glycerate dehydrogenase deficiency; Glyceric aciduria; Glyoxylate reductase/hydroxypyruvate reductase deficiency; HP2; Oxalosis 2; OXALOSIS II; Primary hyperoxaluria type 2
SNOMED CT: Deficiency of glyoxylate reductase (40951006); Deficiency of glycerate dehydrogenase (40951006); Oxalosis type II (40951006); Primary hyperoxaluria type II (40951006); Primary hyperoxaluria, type II (40951006); Glyoxylate reductase deficiency (40951006); Glyceric dehydrogenase deficiency (40951006); L-glyceric aciduria (40951006); Glycerate dehydrogenase deficiency (40951006)
Modes of inheritance:
Autosomal recessive inheritance
MedGen UID:
141025
Concept ID:
C0441748
Intellectual Product
Source: Orphanet
A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in individuals with two pathogenic alleles, either homozygotes (two copies of the same mutant allele) or compound heterozygotes (whereby each copy of a gene has a distinct mutant allele).
 
Gene (location): GRHPR (9p13.2)
 
Monarch Initiative: MONDO:0009824
OMIM®: 260000
Orphanet: ORPHA93599

Disease characteristics

Excerpted from the GeneReview: Primary Hyperoxaluria Type 2
Primary hyperoxaluria type 2 (PH2), caused by deficiency of the enzyme glyoxylate reductase/hydroxypyruvate reductase (GR/HPR), is characterized by recurrent nephrolithiasis (deposition of calcium oxalate in the renal pelvis / urinary tract), nephrocalcinosis (deposition of calcium oxalate in the renal parenchyma), and end-stage kidney disease (ESKD). After ESKD, oxalosis (widespread tissue deposition of calcium oxalate) usually develops. Symptom onset is typically in childhood. [from GeneReviews]
Authors:
Gill Rumsby  |  Sally-Anne Hulton   view full author information

Additional description

From MedlinePlus Genetics
There are three types of primary hyperoxaluria that differ in their severity and genetic cause. In primary hyperoxaluria type 1, kidney stones typically begin to appear anytime from childhood to early adulthood, and ESRD can develop at any age. Primary hyperoxaluria type 2 is similar to type 1, but ESRD develops later in life. In primary hyperoxaluria type 3, affected individuals often develop kidney stones in early childhood, but few cases of this type have been described so additional signs and symptoms of this type are unclear.

Primary hyperoxaluria results from the overproduction of a substance called oxalate. Oxalate is filtered through the kidneys and excreted as a waste product in urine, leading to abnormally high levels of this substance in urine (hyperoxaluria). During its excretion, oxalate can combine with calcium to form calcium oxalate, a hard compound that is the main component of kidney and bladder stones. Deposits of calcium oxalate can damage the kidneys and other organs and lead to blood in the urine (hematuria), urinary tract infections, kidney damage, ESRD, and injury to other organs. Over time, kidney function decreases such that the kidneys can no longer excrete as much oxalate as they receive. As a result oxalate levels in the blood rise, and the substance gets deposited in tissues throughout the body (systemic oxalosis), particularly in bones and the walls of blood vessels. Oxalosis in bones can cause fractures.

Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. The condition often results in end stage renal disease (ESRD), which is a life-threatening condition that prevents the kidneys from filtering fluids and waste products from the body effectively.  https://medlineplus.gov/genetics/condition/primary-hyperoxaluria

Clinical features

From HPO
Hematuria
MedGen UID:
5488
Concept ID:
C0018965
Disease or Syndrome
The presence of blood in the urine. Hematuria may be gross hematuria (visible to the naked eye) or microscopic hematuria (detected by dipstick or microscopic examination of the urine).
Hyperoxaluria
MedGen UID:
43782
Concept ID:
C0020500
Disease or Syndrome
Primary hyperoxaluria is a rare condition characterized by recurrent kidney and bladder stones. The condition often results in end stage renal disease (ESRD), which is a life-threatening condition that prevents the kidneys from filtering fluids and waste products from the body effectively.\n\nPrimary hyperoxaluria results from the overproduction of a substance called oxalate. Oxalate is filtered through the kidneys and excreted as a waste product in urine, leading to abnormally high levels of this substance in urine (hyperoxaluria). During its excretion, oxalate can combine with calcium to form calcium oxalate, a hard compound that is the main component of kidney and bladder stones. Deposits of calcium oxalate can damage the kidneys and other organs and lead to blood in the urine (hematuria), urinary tract infections, kidney damage, ESRD, and injury to other organs. Over time, kidney function decreases such that the kidneys can no longer excrete as much oxalate as they receive. As a result oxalate levels in the blood rise, and the substance gets deposited in tissues throughout the body (systemic oxalosis), particularly in bones and the walls of blood vessels. Oxalosis in bones can cause fractures.\n\nThere are three types of primary hyperoxaluria that differ in their severity and genetic cause. In primary hyperoxaluria type 1, kidney stones typically begin to appear anytime from childhood to early adulthood, and ESRD can develop at any age. Primary hyperoxaluria type 2 is similar to type 1, but ESRD develops later in life. In primary hyperoxaluria type 3, affected individuals often develop kidney stones in early childhood, but few cases of this type have been described so additional signs and symptoms of this type are unclear.
Nephrocalcinosis
MedGen UID:
10222
Concept ID:
C0027709
Disease or Syndrome
Nephrocalcinosis is the deposition of calcium salts in renal parenchyma.
Renal insufficiency
MedGen UID:
332529
Concept ID:
C1565489
Disease or Syndrome
A reduction in the level of performance of the kidneys in areas of function comprising the concentration of urine, removal of wastes, the maintenance of electrolyte balance, homeostasis of blood pressure, and calcium metabolism.
Calcium oxalate urolithiasis
MedGen UID:
318935
Concept ID:
C1833683
Disease or Syndrome
Kleta (2006) reviewed aspects of renal stone disease. Nephrolithiasis and urolithiasis remain major public health problems of largely unknown cause. While disorders such as cystinuria (220100) and primary hyperoxaluria (see 259900) that have nephrolithiasis as a major feature have advanced understanding of the metabolic and physiologic processes of stone formation in general, they have not addressed the etiology of calcium oxalate stone formation, responsible for approximately 75% of urolithiasis cases in humans. Men are affected twice as often as women, but children show no such gender bias. The recurrence rate is also high. In populations of European ancestry, 5 to 10% of adults experience the painful precipitation of calcium oxalate in their urinary tracts. Thorleifsson et al. (2009) noted that between 35 and 65% of hypercalciuric stone formers and up to 70% of subjects with hypercalciuria have relatives with nephrolithiasis, and twin studies have estimated the heritability of kidney stones to be 56%. Genetic Heterogeneity of Calcium Oxalate Nephrolithiasis See also CAON2 (620374), caused by mutation in the OXGR1 gene (606922) on chromosome 13q32.
Abnormality of urine calcium concentration
MedGen UID:
869017
Concept ID:
C4023434
Finding
An abnormality of calcium concentration in the urine.
Elevated urinary L-glycerate level
MedGen UID:
1053674
Concept ID:
CN377500
Finding
The amount of L-glycerate in the urine, normalized for urine concentration, is above the upper limit of normal.
Metabolic acidosis
MedGen UID:
65117
Concept ID:
C0220981
Pathologic Function
Metabolic acidosis (MA) is characterized by a fall in blood pH due to a reduction of serum bicarbonate concentration. This can occur as a result of either the accumulation of acids (high anion gap MA) or the loss of bicarbonate from the gastrointestinal tract or the kidney (hyperchloremic MA). By definition, MA is not due to a respirary cause.
Abnormal circulating creatinine concentration
MedGen UID:
866751
Concept ID:
C4021101
Finding
An abnormal concentration of creatinine in the blood.
Reduced hepatic glyoxylate reductase activity
MedGen UID:
1053899
Concept ID:
CN377470
Finding
Activity of glyoxylate reductase/hydroxypyruvate reductase (GRHPR; EC 1.1.1.79) in liver below the lower limit of normal.

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
Follow this link to review classifications for Primary hyperoxaluria, type II in Orphanet.

Professional guidelines

PubMed

Inoue Y, Shinka T, Ohse M, Kuhara T
J Chromatogr B Analyt Technol Biomed Life Sci 2005 Aug 25;823(1):2-6. Epub 2005 Apr 25 doi: 10.1016/j.jchromb.2005.03.036. PMID: 16055048
Morgan SH, Watts RW
Adv Nephrol Necker Hosp 1989;18:95-106. PMID: 2493726

Recent clinical studies

Etiology

Oppici E, Dindo M, Conter C, Borri Voltattorni C, Cellini B
Handb Exp Pharmacol 2018;245:313-343. doi: 10.1007/164_2017_59. PMID: 29071511
Haworth JC, Dilling LA, Seargeant LE
CMAJ 1991 Jul 15;145(2):123-9. PMID: 1650287Free PMC Article

Diagnosis

Valoti E, Alberti M, Carrara C, Breno M, Yilmaz Keskin E, Bresin E, Cuccarolo P, Açikgöz Y, Benigni A, Noris M, Remuzzi G, Mele C
Nephron 2019;142(3):264-270. Epub 2019 Mar 19 doi: 10.1159/000497823. PMID: 30889567
Hoppe B
Nat Rev Nephrol 2012 Jun 12;8(8):467-75. doi: 10.1038/nrneph.2012.113. PMID: 22688746
Schulze MR, Wachter R, Schmeisser A, Fischer R, Strasser RH
Clin Res Cardiol 2006 Apr;95(4):235-40. Epub 2006 Feb 17 doi: 10.1007/s00392-006-0362-2. PMID: 16598594
Cramer SD, Ferree PM, Lin K, Milliner DS, Holmes RP
Hum Mol Genet 1999 Oct;8(11):2063-9. doi: 10.1093/hmg/8.11.2063. PMID: 10484776
Morgan SH, Watts RW
Adv Nephrol Necker Hosp 1989;18:95-106. PMID: 2493726

Therapy

Oppici E, Dindo M, Conter C, Borri Voltattorni C, Cellini B
Handb Exp Pharmacol 2018;245:313-343. doi: 10.1007/164_2017_59. PMID: 29071511

Prognosis

Webster KE, Ferree PM, Holmes RP, Cramer SD
Hum Genet 2000 Aug;107(2):176-85. doi: 10.1007/s004390000351. PMID: 11030416
Cramer SD, Ferree PM, Lin K, Milliner DS, Holmes RP
Hum Mol Genet 1999 Oct;8(11):2063-9. doi: 10.1093/hmg/8.11.2063. PMID: 10484776
Chlebeck PT, Milliner DS, Smith LH
Am J Kidney Dis 1994 Feb;23(2):255-9. doi: 10.1016/s0272-6386(12)80981-4. PMID: 8311084

Clinical prediction guides

Webster KE, Ferree PM, Holmes RP, Cramer SD
Hum Genet 2000 Aug;107(2):176-85. doi: 10.1007/s004390000351. PMID: 11030416
Cramer SD, Ferree PM, Lin K, Milliner DS, Holmes RP
Hum Mol Genet 1999 Oct;8(11):2063-9. doi: 10.1093/hmg/8.11.2063. PMID: 10484776

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...